MA – October 5, 2009 – BioChemics, Inc. a company “enhancing drug delivery
through biophysical modulation,” is pleased to announce the signing of
a research collaboration agreement with Unilever, one of the world’s
largest consumer goods companies, to utilize BioChemics’ proprietary
topical delivery technology for the delivery of Unilever’s compounds.
"We are delighted to be working with Unilever to evaluate the broader applications
of our technology for their products," said President and Chief Executive Officer John J. Masiz, Esq.
“In addition to our other ongoing collaborations, this agreement further
validates the impact for our proprietary topical technology, making us
attractive to a wide variety of partners to develop well-differentiated,
cost-effective products for consumers.”
About BioChemics, Inc.
BioChemics is a pharmaceutical company that has developed a novel, transdermal
drug delivery system for the first time that may allow almost any drug
to be efficiently delivered through the skin. The transdermal technology,
called VALE® (Vaso-active Lipid Encapsulated), may allow a substantial
portion of the pharmacopeia to be re-engineered, turning oral drugs
into transdermals that are safer (no gastro-intestinal problems), cheaper
and potentially faster acting (applied directly to the treated area)
than oral equivalents. The company's focus is on multi-billion dollar
market opportunities currently underserved by existing therapies. The
company's two lead clinical products focus on treating diabetic peripheral
neuropathy and osteoarthritis. Founded in 1989, the Company is headquartered
in Danvers, Massachusetts. Additional information is available at http://www.biochemics.com.